- Home
- PHLT vs CMPX Comparison
PHLT vs CMPX Comparison
Compare PHLT & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHLT
- CMPX
- Stock Information
- Founded
- PHLT 1976
- CMPX 2014
- Country
- PHLT United States
- CMPX United States
- Employees
- PHLT N/A
- CMPX N/A
- Industry
- PHLT Other Consumer Services
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- PHLT Consumer Discretionary
- CMPX Health Care
- Exchange
- PHLT Nasdaq
- CMPX Nasdaq
- Market Cap
- PHLT 215.3M
- CMPX 214.6M
- IPO Year
- PHLT N/A
- CMPX N/A
- Fundamental
- Price
- PHLT $2.43
- CMPX $2.61
- Analyst Decision
- PHLT
- CMPX Strong Buy
- Analyst Count
- PHLT 0
- CMPX 4
- Target Price
- PHLT N/A
- CMPX $13.75
- AVG Volume (30 Days)
- PHLT 168.5K
- CMPX 2.2M
- Earning Date
- PHLT 03-11-2025
- CMPX 11-12-2024
- Dividend Yield
- PHLT N/A
- CMPX N/A
- EPS Growth
- PHLT N/A
- CMPX N/A
- EPS
- PHLT N/A
- CMPX N/A
- Revenue
- PHLT $120,782,000.00
- CMPX $850,000.00
- Revenue This Year
- PHLT $9.72
- CMPX N/A
- Revenue Next Year
- PHLT $9.90
- CMPX $613.39
- P/E Ratio
- PHLT N/A
- CMPX N/A
- Revenue Growth
- PHLT 9.39
- CMPX N/A
- 52 Week Low
- PHLT $2.29
- CMPX $0.77
- 52 Week High
- PHLT $4.35
- CMPX $2.73
- Technical
- Relative Strength Index (RSI)
- PHLT N/A
- CMPX 77.12
- Support Level
- PHLT N/A
- CMPX $2.34
- Resistance Level
- PHLT N/A
- CMPX $2.70
- Average True Range (ATR)
- PHLT 0.00
- CMPX 0.29
- MACD
- PHLT 0.00
- CMPX 0.12
- Stochastic Oscillator
- PHLT 0.00
- CMPX 90.98
About PHLT Performant Healthcare Inc. Common Stock
Performant Healthcare Inc delivers payment integrity solutions for its healthcare payer clients.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.